Why the Word Peptide Covers Four Very Different Things

The word "peptide" now appears on prescription labels, in compounding pharmacies, in laboratory catalogues and on skincare shelves. It describes a type of molecule rather than a level of evidence, and the four categories it covers differ enormously in how much is actually known about them and in who has been required to prove it. Telling them apart matters more than any single claim attached to any of them.

A peptide is not a category of product. It is a description of a molecule: a short chain of amino acids, the same building blocks that make up proteins, only shorter. Insulin is a peptide. So is the collagen powder sold in health food shops. So is a compound sitting in a freezer in a university laboratory.

That is the root of the confusion. The word describes chemistry rather than status. It says something about structure and nothing at all about whether a substance has been tested in humans, reviewed by a regulator, or evaluated for safety in anyone at all.

The result is one word doing four very different jobs, often inside the same conversation.

Approved peptide medicines have cleared a specific bar

This is the oldest and most rigorously evidenced category. Insulin has been in clinical use for more than a century. Teriparatide is prescribed for osteoporosis. Octreotide is used in specific hormonal conditions. More recently, semaglutide and tirzepatide have become widely recognised names.

What these share is not chemistry. It is process. Each has moved through controlled clinical trials, been submitted for regulatory review, and been approved for named conditions in named populations. Each carries an approved label stating what it is for, who it is for, and what is known about its risks.

That label is the entire point. An approved peptide medicine is not simply a substance that does something. It is a substance whose effects, limits and side effects have been documented thoroughly enough that a regulator will permit specific claims to be made about it.

Approval of this kind typically follows years of trials across escalating numbers of participants, with predefined endpoints and independent scrutiny of the results. The claims that survive that process are usually narrower than the ones the compound started out promising. Everything in the three categories that follow lacks this.

Compounded preparations are not the same as approved products

Compounding pharmacies prepare medicines tailored to an individual patient, for example at a different strength or without a particular allergen. It is a legitimate and long-established part of healthcare.

Compounded preparations are not approved products, however. Approval applies to a specific manufacturer's product made under specific conditions. A compounded version of the same active ingredient has not been through that review, even when the underlying drug has.

This became widely visible during recent shortages of GLP-1 medicines, when compounded versions circulated at scale and the FDA issued warnings about dosing errors and about salt forms being substituted for the approved active ingredient. The agency has also flagged certain peptides as a safety concern in compounded preparations, and its position on several is still evolving.

Compounded does not mean approved. It describes something narrower, and more conditional, than the word tends to suggest.

Research compounds are sold for laboratory use only

This is the category most people encounter online without recognising what it is.

A large number of peptides are sold strictly for laboratory research. They are not approved for human or veterinary use and are not intended for it. The evidence behind them is typically preclinical, meaning cell cultures or animal models, and in many cases a single promising study is carrying a great deal of subsequent enthusiasm.

Preclinical is not proof. A result in a mouse indicates that a hypothesis is worth testing. It does not establish what happens in a person, at what exposure, over what period, or with what risk. Most compounds that look promising at this stage never survive human trials, and that is the ordinary outcome of the process rather than a failure of it.

Laboratories sourcing these materials generally work with suppliers of research-use-only peptides that publish lot-specific certificates of analysis issued by independent accredited laboratories, so the identity and purity of a given batch can be checked against a document rather than assumed.

The important point is what that documentation can and cannot establish. A certificate of analysis confirms what a substance is. It says nothing about what that substance does in a human body, and the two questions are routinely confused by people reading the same document. 

Cosmetic and supplement peptides sit outside the medicines system

The fourth category is already in most bathrooms and kitchens.

Topical peptides appear in skincare, where they are regulated as cosmetics. Collagen peptides appear in powders and drinks, where they are regulated as food or as dietary supplements. Neither route involves the pre-market approval a medicine requires, and neither permits claims to treat or prevent disease.

Risk in this category is generally low. The issue is not safety so much as inference. A peptide in a serum and a peptide in a clinical trial can share a name and a molecular family while having almost nothing else in common, including the evidence behind them.

Marketing tends to exploit that overlap. 

A label can reference peptides and gesture toward impressive-sounding research without ever claiming that this product, at this concentration, was the thing studied. The claim is usually about the category rather than the bottle, and the two are easy to conflate when they appear in the same sentence.

The categories differ in what is known, not in how interesting they sound

Ranking these four by scientific interest produces a different order than ranking them by evidence. A compound can be genuinely fascinating and still sit a very long way from anything established in humans.

It is also worth noticing where enthusiasm tends to concentrate. The louder claims usually cluster around the categories with the least oversight, because those are precisely the categories where nobody is required to substantiate anything.

A short set of questions separates them in practice:

• Has a regulator approved this substance for a named condition in a named population?

• If it was prepared by a pharmacy, is that the same thing as the approved product, or a variation on it?

• Is the available evidence from humans, or from cells and animals?

• What does the accompanying documentation actually certify, and what does it leave unanswered?

• Is the claim being made about this specific product, or about the broader category it belongs to?

Reading the word carefully is most of the work

None of this requires a background in biochemistry. It requires slowing down at the word itself and establishing which of the four categories is in play before weighing anything said about it.

Approved medicines arrive with a label and a named indication. Compounded preparations come from a pharmacy and are not equivalent to an approved product. Research compounds arrive with a certificate of analysis and an explicit statement that they are not for human use. Cosmetic and supplement peptides arrive with neither approval nor permission to make medical claims.

Four categories, four very different standards of proof, one word covering all of them. The word itself is the least informative thing on the label.

Disclaimer: This article is provided for general educational and informational purposes only. It is not intended to provide medical advice, diagnosis, treatment, or recommendations. Readers should consult a qualified healthcare professional for advice about their individual health, medications, or treatment options.